Inhibiting the PD-1/PD-L1 pathway has the potential to reinstate T-cell functionality and effectively suppress Treg cells within the TME, thereby eliciting an anti-tumor immune response [32,33]. This evidence concerns the gene PDCD1 and neoplasm.